To summarize research progress in small-molecule targeted agents against major driver oncogenes in non-small cell lung cancer (NSCLC).
Approach:
Overview of NSCLC: Discusses the prevalence, prognosis, and treatment challenges of NSCLC, emphasizing the role of molecular targeted therapy.
Targeted Agents: Elaborates on the mechanism of action, clinical efficacy, and treatment-related adverse events of various generations of inhibitors targeting EGFR, ALK, and KRAS.
Emerging Therapies: Integrates clinical data on investigational small-molecule targeted drugs addressing emerging oncogenic drivers like RAS, HER2, and SRC.
Key Findings:
NSCLC accounts for approximately 85% of lung cancer cases and has a poor prognosis.
Current targeted drugs face limitations such as acquired drug resistance and insufficient blood-brain barrier penetration.
Interpretation:
Future research should focus on accelerating clinical translation of investigational drugs, exploring combination regimens, and identifying novel molecular targets.
Limitations:
Current targeted therapies are limited by acquired drug resistance.
Insufficient penetration of drugs across the blood-brain barrier remains a challenge.
Conclusion:
Continued advancements in small-molecule targeted therapies are essential for improving clinical outcomes in NSCLC.
